Table 3.

Cotinine level and CPD per allele in current smokers in the EPIC lung cancer study

SNPExpected effect on CPD and cotinine (7,8)CPD (n)Cotinine level (nmol/L)
NMean (95% CI)NMean (95% CI)
rs215614 (7p14, PDE1C)
AALow level28016.8 (15.7–17.9)3401,317.1 (1,205.3–1,429)
AG35215.7 (14.7–16.7)4101,268.4 (1,159.6–1,377.3)
GGHigh level8815.9 (14–17.7)1021,269.9 (1,120.5–1,419.3)
Trend testa:β = −0.7, SE = 0.5, P = 0.15β = −31.7, SE = 32.2, P = 0.33
rs13273442 (8p11, CHRNB3)
GGHigh level44716.3 (15.4–17.2)5361,295.2 (1,190.9–1,399.5)
GA22716.2 (15–17.4)2731,268.5 (1,156.2–1,380.7)
AALow level4217.2 (14.7–19.7)441,328.5 (1,127.5–1,529.4)
Trend testa:β = 0.2, SE = 0.5, P = 0.72β = −6.4, SE = 35.6, P = 0.86
rs1329650 (10q23)
GGHigh level38316.1 (15.1–17)4451,292 (1,186.1–1,397.8)
GT25516.4 (15.3–17.5)3131,291.1 (1,179.6–1,402.6)
TTLow level6417.1 (15.1–19.2)761,302.4 (1,134.1–1,470.7)
Trend testa:β = 0.5, SE = 0.5, P = 0.32β = 2.8, SE = 32.5, P = 0.93
rs1028936 (10q23)
AAHigh level49516 (15.1–16.9)5881,298.4 (1,194.9–1,401.9)
AC19516.3 (15–17.5)2341,254.4 (1,135.1–1,373.7)
CCLow level3117.3 (14.5–20.2)351,215.6 (990.7–1,440.5)
Trend testa:β = 0.4, SE = 0.5, P = 0.42β = −42.9, SE = 37.9, P = 0.26
rs16969968 (15q25, CHRNA5)
GGLow level28015.9 (14.8–17)3311,176.7 (1,063.9–1,289.4)
GA34816.4 (15.4–17.3)4171,301 (1,195–1,406.9)
AAHigh level13116.6 (15.2–18.1)1611,357.1 (1,231–1,483.2)
Trend testa:β = 0.4, SE = 0.4, P = 0.35β = 96, SE = 28.8, P = 0.001
rs578776 (15q25, CHRNA3)
GGHigh level39416.7 (15.8–17.7)4811,339 (1,231.6–1,446.4)
GA28115.6 (14.5–16.6)3241,229.7 (1,113.5–1,346)
AALow level3215.3 (12.5–18)391,276 (1,058.8–1,493.1)
Trend testa:β = −1, SE = 0.5, P = 0.06β = −77.4, SE = 36.2, P = 0.03
rs4105144 (19q13, CYP2A6)
CCHigh level33516.1 (15.1–17.1)3941,193.2 (1,086.3–1,300.2)
CT28716.5 (15.4–17.6)3431,330.5 (1,218.6–1,442.3)
TTLow level8116.4 (14.5–18.3)1081,413.6 (1,277.2–1,550.1)
Trend testa:β = 0.2, SE = 0.5, P = 0.65β = 118.3, SE = 30.2, P = 0.0001
rs3733829 (19q13)
AALow level29916.2 (15.1–17.2)3561,312.1 (1,201.5–1,422.6)
AG31416.5 (15.4–17.5)3831,283.1 (1,172.9–1,393.3)
GGHigh level9815.9 (14.3–17.6)1071,168.4 (1,019.7–1,317)
Trend testa:β = −0.02, SE = 0.4, P = 0.97β = −59.5, SE = 31.1, P = 0.06
rs7937 (19q13, RAB4B)
TTHigh level22716.3 (15.2–17.5)2641,176.1 (1,059.9–1,292.2)
TC33916.3 (15.3–17.3)4091,340.1 (1,231.2–1,448.9)
CCLow level15316.3 (14.9–17.7)1801,332.1 (1,211.8–1,452.3)
Trend test*:β = −0.01, SE = 0.4, P = 0.98β = 86.3, SE = 29.3, P = 0.003
rs7260329 (19q13, CYP2B6)
CCHigh level38316.2 (15.2–17.1)4431,275.2 (1,168.3–1,382)
CT27316.7 (15.6–17.8)3311,304.6 (1,194.1–1,415.2)
TTLow level6615.6 (13.5–17.6)781,320.1 (1,156.6–1,483.6)
Trend testa:β = 0.02, SE = 0.5, P = 0.97β = 25.2, SE = 32.2, P = 0.43

R2 between the SNPs are less than 0.50.

  • aLinear trends in CPD and cotinine levels were assessed by linear regression models adjusted for center, gender, and case–control status.